Omeprazole/sodium bicarbonate powder suspension - Salix Pharmaceuticals

Drug Profile

Omeprazole/sodium bicarbonate powder suspension - Salix Pharmaceuticals

Alternative Names: Acitrel; Omez Insta; Rapinex Powder for Oral Suspension; SAN 05; Zegerid Powder for Oral Suspension

Latest Information Update: 07 Apr 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Santarus
  • Developer Norgine; Salix Pharmaceuticals
  • Class Antiulcers; Gastric antisecretories
  • Mechanism of Action Antacids; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Gastrointestinal haemorrhage

Most Recent Events

  • 01 Apr 2015 Salix Pharmaceuticals has been acquired by Valeant Pharmaceuticals International
  • 02 Jan 2014 Santarus has been acquired and merged into Salix Pharmaceuticals
  • 01 Feb 2011 Norgine completes a Phase-I trial in Duodenal ulcer, Erosive oesophagitis and Gastro-oesophageal reflux (in volunteers) in United Kingdom (NCT01710995)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top